Navigation Links
Pharmaceutical advances offer new options for health outcomes
Date:5/20/2013

Orlando, FL (May 20, 2013) Research presented at Digestive Disease Week (DDW) explores pharmaceutical advances for treating irritable bowel syndrome with diarrhea (IBS-D) and hepatitis C.

An international study holds promising results for patients suffering from IBS-D. In the phase II study, researchers found that the drug ibodutant significantly improved symptoms in more than 50 percent of the individuals treated.

"While there's been a lot of progress in medicines for IBS with constipation, we haven't seen the same in IBS with diarrhea," said Jan Tack, MD, professor and director of the division of gastroenterology and internal medicine at Leuven University in Belgium. "Up to this point, we haven't been able to provide a pharmaceutical option for this patient group that successfully manages the pain associated with the condition."

IBS is an extremely common condition, affecting an estimated 10 percent of adults. Funded by Menarini, the double-blind, multinational study recruited 559 patients with IBS-D who were randomized and treated with 1, 3 or 10 mg of ibodutant or a placebo. Patients took an oral tablet once daily for eight consecutive weeks. Researchers found that 10 mg was the most effective dose and that it worked best for females.

"These are exciting findings that could bring a lot of relief to many patients," said Dr. Tack said. "We're looking forward to moving into phase III to confirm our findings with a much larger sample of patients."

New therapy for patients with hepatitis C examined

New research suggests that an investigational therapy for patients with hepatitis C can achieve high response rates in a wide range of patients, even those who respond poorly to current treatments. The study examined the safety and efficacy of interferon-free regimens, including three direct-acting antiviral drugs with and without ribavirin, for 12 or 24 weeks, in patients with chronic hepatitis C who were e
'/>"/>

Contact: Aimee Frank
newsroom@gastro.org
407-685-4030
Digestive Disease Week
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Active Pharmaceutical Ingredients (API) Market in Europe Will Reach $38,255.67 Million By 2017- Pricing and Reimbursement Initiatives Supporting Generic Drug Growth
2. Cloud Computing in Pharmaceutical Research and Development - Virtualization of Data through the Cloud Optimizes Next-Generation DNA Sequencing and Clinical Trials Data
3. Aeolus Pharmaceuticals To Present At Taglich Brothers 10th Annual Small Cap Equity Conference
4. TraceLink Leads Pharmaceutical Track and Trace, Big Data and Cloud-based Supply Networks Discussion at LogiPharma Europe Conference
5. Corporate Whistle Blower Center Now Urges Pharmaceutical Insiders Or Physicians To Become A Whistleblower If They Can Prove A Drug Maker Was Knowingly Involved In Bribery
6. Pharmaceutical advertising down but not out
7. Pharmaceutical companies: An $84 million marketing effort in the District of Columbia
8. Survey shows medical students have frequent interactions with pharmaceutical companies
9. Radiopharmaceuticals Market - New Industry Research Report Published by Transparency Market Research
10. Sewage lagoons remove most -- but not all -- pharmaceuticals
11. Pharmaceutical Manufacturing in China Industry Research Report – Now Available from IBISWorld
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... India (PRWEB) July 31, 2014 RankingBySEO, ... service for those individuals and organizations against whom negative ... as ‘Remove Negative Comments Service’. , About the ... “We have officially announced the service now, but we ... rid of negative comments for several years.” , On ...
(Date:7/31/2014)... 31, 2014 T.E.N., a technology ... honored finalists and winners Wednesday evening, July 30, ... Awards Gala at the Westin St. Francis in ... information security for the BlackLine Systems, was selected ... Award winner for the ISE® West Region. As ...
(Date:7/31/2014)... Steven Reinberg HealthDay Reporter ... regulation of electronic cigarettes isn,t warranted based on current ... contrary, allowing e-cigarettes to compete with regular cigarettes might ... reviewing 81 prior studies on the use and safety ... suggests that there is a potential for smokers to ...
(Date:7/31/2014)... India (PRWEB) July 31, 2014 ... Marketing Company, has introduced a new service named ... , Ethane Web Technologies has designed the service ... of clients and Java Development service being provided ... the company a confidence to promise outstanding Java ...
(Date:7/31/2014)... 2014 Bedros Keuilian’s Fit Body Boot Camp ... other countries. At his annual Fitness Business Summits, some of ... their marketing strategies. But in his latest blog post, he ... marketing a personal training business is to create free ... personal trainer has a certain area that they really feel ...
Breaking Medicine News(10 mins):Health News:RankingBySEO Launches a New Service ‘Remove Negative Comments’ 2Health News:Max Solonski, Caesars Entertainment Claim Top Awards at ISE® West Ralph Johnson (King County, WA) named People’s Choice Award Winner 2Health News:Max Solonski, Caesars Entertainment Claim Top Awards at ISE® West Ralph Johnson (King County, WA) named People’s Choice Award Winner 3Health News:Max Solonski, Caesars Entertainment Claim Top Awards at ISE® West Ralph Johnson (King County, WA) named People’s Choice Award Winner 4Health News:Benefits of E-Cigarettes May Outweigh Harms, Study Finds 2Health News:Benefits of E-Cigarettes May Outweigh Harms, Study Finds 3Health News:Ethane Web Technologies Announces Java Development Service at Pocket Friendly Cost 2Health News:Bedros Keuilian’s New Post Explains the Value of Fitness Information Products in Marketing a Personal Training Business 2Health News:Bedros Keuilian’s New Post Explains the Value of Fitness Information Products in Marketing a Personal Training Business 3
... difference in effectiveness of 5 drugs currently available , , ... that any one of the five drugs available in ... the others, says an American College of Physicians (ACP) ... just issued a new guideline on drug treatment of ...
... Publishing, an award-winning interactive, visual content developer, today ... the first free, Web-based 3-D interactive model of ... educators, and health and medical professionals, The Visible ... how the human body works. It will also ...
... ANNAPOLIS, Md., March 4 Dozens of ... gathered in Annapolis today as,the General Assembly ... regulations, protections against identity theft, and the ... visited legislators,offices and attended committee hearings on ...
... Market Segments, CHICAGO, March 4 Throw ... Financial services firms, insurers, and,healthcare payors admit they ... to serve baby boomers, who will control some ... who make up the wealthiest generation in history, ...
... CA A nuclear receptor protein, known for controlling ... powerful anti-inflammatory effects in arteries, suppressing atherosclerosis in mice ... research by scientists at the Salk Institute for Biological ... , Their findings, reported in this weeks online edition ...
... swayed by adolescent drug use trends , , TUESDAY, March 4 ... boys are more likely to give up the habit if ... no matter what, new research shows. , The findings ... to the wider world,s embrace of illegal drugs, said study ...
Cached Medicine News:Health News:Groups Issue New Dementia Drug Guidelines 2Health News:Argosy publishing launches The Visible Body 2Health News:Argosy publishing launches The Visible Body 3Health News:Utilities, Long Term Care Bills at Center of 'AARP Day In Annapolis' 2Health News:Diamond's Retirement Study Finds Companies Ill-Prepared to Meet Baby Boomers' Health and Wealth Needs 2Health News:Diamond's Retirement Study Finds Companies Ill-Prepared to Meet Baby Boomers' Health and Wealth Needs 3Health News:Diamond's Retirement Study Finds Companies Ill-Prepared to Meet Baby Boomers' Health and Wealth Needs 4Health News:Diamond's Retirement Study Finds Companies Ill-Prepared to Meet Baby Boomers' Health and Wealth Needs 5Health News:New potential drug target for the treatment of atherosclerosis 2Health News:New potential drug target for the treatment of atherosclerosis 3Health News:Troubled Boys Will Abandon Pot When It's Deemed Uncool 2
(Date:7/31/2014)... -- HeartWare International, Inc . (NASDAQ: ... circulatory support technologies that are revolutionizing the treatment of ... for the second quarter ended June 30, 2014, a ... the same period of 2013. During the ... were sold globally compared to 523 units in the ...
(Date:7/31/2014)... 2014 Second Quarter Total Revenue $2.0 billion; an increase of ... 4% for same store sales and 8% pro forma, excluding ... , 2014 Second Quarter GAAP EPS $0.37; Cash EPS $1.91, ... Operating Cash Flow $376 million; Adjusted Operating Cash Flow $500 ... Launched 17 new products in the U.S. year-to-date , ...
(Date:7/31/2014)... , 31 juli 2014 De Pfizer ... een rekruteringscampagne voor gezonde vrijwilligers van Japanse komaf voor ... gevestigde PCRU is één van twee onderzoekseenheden ... als ideaal levens te verbeteren door de ontdekking en ... de PCRU op zoek naar mannen en vrouwen van ...
Breaking Medicine Technology:HeartWare International Reports $70.1 Million In Second Quarter 2014 Revenue; 38% Increase From Second Quarter 2013 2HeartWare International Reports $70.1 Million In Second Quarter 2014 Revenue; 38% Increase From Second Quarter 2013 3HeartWare International Reports $70.1 Million In Second Quarter 2014 Revenue; 38% Increase From Second Quarter 2013 4HeartWare International Reports $70.1 Million In Second Quarter 2014 Revenue; 38% Increase From Second Quarter 2013 5HeartWare International Reports $70.1 Million In Second Quarter 2014 Revenue; 38% Increase From Second Quarter 2013 6HeartWare International Reports $70.1 Million In Second Quarter 2014 Revenue; 38% Increase From Second Quarter 2013 7HeartWare International Reports $70.1 Million In Second Quarter 2014 Revenue; 38% Increase From Second Quarter 2013 8HeartWare International Reports $70.1 Million In Second Quarter 2014 Revenue; 38% Increase From Second Quarter 2013 9HeartWare International Reports $70.1 Million In Second Quarter 2014 Revenue; 38% Increase From Second Quarter 2013 10HeartWare International Reports $70.1 Million In Second Quarter 2014 Revenue; 38% Increase From Second Quarter 2013 11HeartWare International Reports $70.1 Million In Second Quarter 2014 Revenue; 38% Increase From Second Quarter 2013 12Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 2Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 3Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 4Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 5Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 6Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 7Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 8Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 9Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 10Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 11Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 12Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 13Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 14Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 15Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 16Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 17Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 18Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 19Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 20Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 21Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 22Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 23Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 24Valeant Pharmaceuticals Reports Second Quarter 2014 Financial Results 25
... PARSIPPANY, N.J., Sept. 15, 2011 Fidia Farmaceutici S.p.A. ... ® (sodium hyaluronate), an injectable treatment for knee ... and physical therapy are not enough, will be transferred ... 24, 2011.  Fidia Farmaceutici S.p.A. is the owner and ...
... September 15, 2011 Oramed Pharmaceuticals Inc. ... oral delivery systems, announced today that Ehud Arbit, M.D., ... present at the 8th Annual Israel Strategic Partner and ... Bristol-Myers Squibb Pharmaceutical Research Institute in Princeton, NJ on ...
Cached Medicine Technology:HYALGAN® (sodium hyaluronate) Commercial Rights Transfer Back to Fidia Farmaceutici S.p.A. 2Oramed Pharmaceuticals Chosen to Present at the 8th Annual Israel Strategic Partner and Venture Conference on September 22, 2011 2
... Sickle-Chex is a positive and negative ... presence of Hemoglobin S in solubility tests ... Streck SICKLEDEX and other manufacturers' solubility ... plastic squeeze dropper vial. The vial dispenses ...
... whole blood hematology control manufactured specifically for ... and the Coulter AcT5diff instruments. The composition ... cell differential, positioning the populations within the ... The product offers 105-day closed-vial stability and ...
... STaK-Chex, a whole blood assayed hematology ... five-part white cell differential available with the ... unique product has 14-day open-vial stability, 105-day ... normal and high levels. The 4.0ml pierceable ...
Abiomed introduces its new intra-aortic balloon (IAB); an easy-to-insert, minimally invasive technology designed to enhance blood flow to the heart and other organs for patients with diminished heart...
Medicine Products: